Palisade Bio, Inc.
PALI- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001357459
In the last 90 days, Palisade Bio, Inc. insiders filed 3 open-market purchases and 2 sales; 124 institutions reported holding it in 13F filings for Q2 2026, worth $362.4M in total; no superinvestor holds it.
Q3 2025 vs. Q2 2025
How the institutions holding Palisade Bio, Inc. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Q3 2025 | Change |
|---|---|---|---|
| Holders | 11 | 12 | +1 |
| Shares | 84.6K | 119.6K | +35.0K (+41.3%) |
| Value | $57.5K | $102.8K | +$45.3K (+78.7%) |
New holders (2)
Institutions that held Palisade Bio, Inc. at the end of Q3 2025 but not at the end of Q2 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Citigroup Inc | 2,347 | $2.02K | 0.00% |
| Rockefeller Capital Management L.P. | 500 | $430 | 0.00% |
Sold out (1)
Institutions that held Palisade Bio, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Transce3nd, LLC | 1,000 | $680 |